The First FDA-Approved Therapy to Improve Renal Function of Adult HRS Patients

This week, in China, Humanwell Healthcare's Class 1.2 traditional Chinese medicine was approved for marketing. Pearl Bio's Bozitinib enteric capsule was planned to be included for priority approval. Several new drugs were approved for clinical trial stages, or the applications for such trials were submitted. While globally, the terlipressin injection became the world's first FDA-approved therapy to improve renal function in adult patients with hepatorenal syndrome (HRS). Besides, several drugs have obtained Fast Track Designation (FTD), and many innovative drugs achieved positive clinical results, despite the fact that there were also a few drug failures.

Other pharma news collected this week features 26 pieces of information covering topics on drug review, R&D, and business. You can get more industry insights and firsthand market information from China to the globe at PharmaSources.com